MAPT and Alzheimer disease: Curcumin has been reported to inhibit most activities of Aβ, including aggregation and Aβ-induced inflammation, in vitro, and oral administration of curcumin can improve behavioral impairments, inhibit Aβ oligomerization and deposition, and inhibit tau phosphorylation in the brains of AD animal models (Hamaguchi et al., 2010).